Nairong Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nairong Xie has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Min Wang
Department of Neurology Xuanwu Hospital, Capital Medical University Beijing China
4 shared publicationsYan Lu
Department of Neurology Xuanwu Hospital, Capital Medical University Beijing China
4 shared publicationsYuting Jiang
Department of Neurology Xuanwu Hospital, Capital Medical University Beijing China
4 shared publicationsHaoran Liu
Department of Neurology Xuanwu Hospital, Capital Medical University Beijing China
3 shared publicationsLi Di
Department of Neurology Xuanwu Hospital, Capital Medical University Beijing China
3 shared publicationsWenjia Zhu
Department of Neurology Xuanwu Hospital, Capital Medical University Beijing China
3 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71104
Association of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross‐Sectional Study
Background: The severity of myasthenia gravis (MG) varies significantly among individuals, yet the factors underlying this heterogeneity are not fully understood. This study aimed to investigate the association between demographic, clinical, and environmental factors and the severity of MG. Methods: From February 2017 to December 2021, adult patients registered in the national MG database were enrolled in this cross‐sectional study. Baseline data on demographic, clinical, and environmental factors (including the natural environment, socioeconomic status, and lifestyle) were collected. Disease severity was classified as mild or moderate to severe using the MG Activities of Daily Living (MG‐ADL) scale and the Quantitative MG (QMG) scale. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for these associations. Results: A total of 2468 patients were included. The median MG‐ADL score was 3.0 (interquartile range [IQR] 1.0–6.0), and the median QMG score was 6.0 (IQR 3.0–9.0). Higher MG‐ADL scores were associated with age at onset ≥ 65 years (OR 1.85, 95% CI 1.32–2.58), underweight (2.03, 1.35–3.06), generalized onset (2.80, 2.26–3.48), and thymoma (1.70, 1.26–2.30). In contrast, overweight or obesity (OR 0.65, 95% CI 0.52–0.82), medium altitudes (0.64, 0.46–0.90), high educational attainment (0.68, 0.49–0.94), and high monthly household income (0.71, 0.53–0.96) were inversely associated with MG‐ADL scores. Factors associated with higher QMG scores included female sex (OR 1.75, 95% CI 1.28–2.37), age at onset ≥ 65 years (1.91, 1.35–2.71), generalized onset (2.50, 2.00–3.13), thymoma (1.97, 1.43–2.71), medium latitudes (1.53, 1.08–2.16), and high altitudes (1.65, 1.10–2.47). Lower QMG scores were correlated with overweight or obesity (OR 0.78, 95% CI 0.61–0.99), thymectomy (0.57, 0.40–0.81), medium altitudes (0.70, 0.49–0.99), and medium sunlight duration (0.67, 0.49–0.93), as well as higher concentrations of particulate matter with an aerodynamic diameter of ≤ 2.5 μm and higher household income. Conclusion: In addition to demographic and clinical factors, environmental factors may also influence MG severity. Further research is warranted to clarify these associations and their underlying mechanisms.
- 25 August 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (8) , e71104
Open AccessAssociation of Demographic, Clinical, and Environmental Factors With Disease Severity in Adult Myasthenia Gravis: A Multicenter Cross‐Sectional Study
Background: The severity of myasthenia gravis (MG) varies significantly among individuals, yet the factors underlying this heterogeneity are not fully understood. This study aimed to investigate the association between demographic, clinical, and environmental factors and the severity of MG. Methods: From February 2017 to December 2021, adult patients registered in the national MG database were enrolled in this cross‐sectional study. Baseline data on demographic, clinical, and environmental factors (including the natural environment, socioeconomic status, and lifestyle) were collected. Disease severity was classified as mild or moderate to severe using the MG Activities of Daily Living (MG‐ADL) scale and the Quantitative MG (QMG) scale. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for these associations. Results: A total of 2468 patients were included. The median MG‐ADL score was 3.0 (interquartile range [IQR] 1.0–6.0), and the median QMG score was 6.0 (IQR 3.0–9.0). Higher MG‐ADL scores were associated with age at onset ≥ 65 years (OR 1.85, 95% CI 1.32–2.58), underweight (2.03, 1.35–3.06), generalized onset (2.80, 2.26–3.48), and thymoma (1.70, 1.26–2.30). In contrast, overweight or obesity (OR 0.65, 95% CI 0.52–0.82), medium altitudes (0.64, 0.46–0.90), high educational attainment (0.68, 0.49–0.94), and high monthly household income (0.71, 0.53–0.96) were inversely associated with MG‐ADL scores. Factors associated with higher QMG scores included female sex (OR 1.75, 95% CI 1.28–2.37), age at onset ≥ 65 years (1.91, 1.35–2.71), generalized onset (2.50, 2.00–3.13), thymoma (1.97, 1.43–2.71), medium latitudes (1.53, 1.08–2.16), and high altitudes (1.65, 1.10–2.47). Lower QMG scores were correlated with overweight or obesity (OR 0.78, 95% CI 0.61–0.99), thymectomy (0.57, 0.40–0.81), medium altitudes (0.70, 0.49–0.99), and medium sunlight duration (0.67, 0.49–0.93), as well as higher concentrations of particulate matter with an aerodynamic diameter of ≤ 2.5 μm and higher household income. Conclusion: In addition to demographic and clinical factors, environmental factors may also influence MG severity. Further research is warranted to clarify these associations and their underlying mechanisms.
- Open Access
- 1 June 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70921
Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety
Aims: To identify factors influencing remission and relapse, and to evaluate the safety of tacrolimus monotherapy (TAMO) in adult‐onset mild‐to‐moderate myasthenia gravis (MG). Methods: This retrospective analysis was conducted on MG patients receiving TAMO. Remission was defined as achieving minimal symptom expression (MSE), and multivariable Cox regression analysis identified predictors of remission and relapse. Cancer risk was assessed by standardized incidence ratio (SIR), based on the age‐specific cancer incidence rates in China in 2022. Results: Among 153 patients, 77.8% achieved MSE, with a median time of 6.0 months. Age at onset (hazard ratio [HR] = 0.982, 95% confidence interval [CI] = 0.968–0.995, p = 0.009) and new‐onset MG (HR = 2.065, 95% CI = 1.266–3.368, p = 0.004) were independent predictors of time to achieving MSE. The optimal cut‐off value for age at onset was 70 years. Relapse occurred in 31% of patients. Tacrolimus concentration at MSE (HR = 0.815, 95% CI = 0.695–0.956, p = 0.012) and dose reduction speed (HR = 1.717, 95% CI = 1.280–2.305, p < 0.001) were independent predictors of relapse. The cut‐off values were 5.30 ng/mL and 1.08 mg/year, respectively. Adverse drug reactions (ADRs) occurred in 45.0% of the 200 patients receiving TAMO, with hyperglycemia being the most common (17.5%). Eight patients developed cancer, and the SIR was 2.86 (95% CI = 1.23–5.63, p = 0.005) compared with the general Chinese population. Conclusion: TAMO was associated with higher rates of MSE in adult‐onset mild‐to‐moderate MG patients with new‐onset disease or with an onset age ≤ 70 years. To avoid MG relapse, tacrolimus concentration > 5.30 ng/mL at MSE and dose reduction speed ≤ 1.08 mg/year can be considered. Cancer surveillance may be considered for elderly patients undergoing long‐term tacrolimus therapy. Limitations include the retrospective, uncontrolled design, moderate sample sizes, and limited follow‐up duration; thus, long‐term safety, particularly cancer risk, requires further validation.
- 1 June 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (6) , e70921
Open AccessTacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety
Aims: To identify factors influencing remission and relapse, and to evaluate the safety of tacrolimus monotherapy (TAMO) in adult‐onset mild‐to‐moderate myasthenia gravis (MG). Methods: This retrospective analysis was conducted on MG patients receiving TAMO. Remission was defined as achieving minimal symptom expression (MSE), and multivariable Cox regression analysis identified predictors of remission and relapse. Cancer risk was assessed by standardized incidence ratio (SIR), based on the age‐specific cancer incidence rates in China in 2022. Results: Among 153 patients, 77.8% achieved MSE, with a median time of 6.0 months. Age at onset (hazard ratio [HR] = 0.982, 95% confidence interval [CI] = 0.968–0.995, p = 0.009) and new‐onset MG (HR = 2.065, 95% CI = 1.266–3.368, p = 0.004) were independent predictors of time to achieving MSE. The optimal cut‐off value for age at onset was 70 years. Relapse occurred in 31% of patients. Tacrolimus concentration at MSE (HR = 0.815, 95% CI = 0.695–0.956, p = 0.012) and dose reduction speed (HR = 1.717, 95% CI = 1.280–2.305, p < 0.001) were independent predictors of relapse. The cut‐off values were 5.30 ng/mL and 1.08 mg/year, respectively. Adverse drug reactions (ADRs) occurred in 45.0% of the 200 patients receiving TAMO, with hyperglycemia being the most common (17.5%). Eight patients developed cancer, and the SIR was 2.86 (95% CI = 1.23–5.63, p = 0.005) compared with the general Chinese population. Conclusion: TAMO was associated with higher rates of MSE in adult‐onset mild‐to‐moderate MG patients with new‐onset disease or with an onset age ≤ 70 years. To avoid MG relapse, tacrolimus concentration > 5.30 ng/mL at MSE and dose reduction speed ≤ 1.08 mg/year can be considered. Cancer surveillance may be considered for elderly patients undergoing long‐term tacrolimus therapy. Limitations include the retrospective, uncontrolled design, moderate sample sizes, and limited follow‐up duration; thus, long‐term safety, particularly cancer risk, requires further validation.
- Open Access
- 13 October 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (10) , e70627
Dynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis
Background: Efgartigimod is a neonatal Fc receptor (FcRn) antagonist that reduces pathogenic IgG and improves clinical symptoms in generalized myasthenia gravis (gMG). However, its immunomodulatory effects on innate and adaptive immune cells beyond IgG depletion are rarely reported. Objective: This study aimed to investigate clinical and immunological responses during the initial treatment cycle of efgartigimod in naive acetylcholine receptor antibody‐positive (AChR‐Ab+) gMG patients, with a focus on peripheral immune cell dynamics. Methods: We conducted a longitudinal study between October 23, 2023, and December 10, 2024, based on the database of the Clinical Cohort Study of Myasthenia Gravis at Xuanwu Hospital, Capital Medical University. Seventeen naive AChR‐Ab+ gMG patients were enrolled after applying strict inclusion and exclusion criteria and received a four‐dose regimen of efgartigimod. Clinical efficacy was evaluated using Myasthenia Gravis Activities of Daily Living (MG‐ADL) and Quantitative Myasthenia Gravis (QMG) scores. Serum total IgG and AChR antibody levels were measured. Peripheral immune cell profiling included leukocytes, neutrophils, monocytes, platelets, and natural killer (NK) cells, as well as T and B cell subsets analyzed by flow cytometry. Longitudinal changes were assessed using linear mixed‐effects models. Results: All patients achieved clinical improvement, accompanied by significant reductions in serum total IgG and AChR antibody levels. Neutrophil and leukocyte counts progressively increased and peaked at Week 3 ( p < 0.05), whereas monocyte and platelet counts remained relatively stable throughout all visits. CD4+ and CD8+ T cells decreased transiently at Week 2 and partially recovered by Week 3 ( p = 0.091 and p = 0.005). The CD4/CD8 ratio remained stable. NK cells showed a temporary decrease at Week 2 with a borderline significant time effect ( p = 0.050), followed by partial recovery. Plasmablast proportions significantly increased at Week 2 ( p < 0.05), with a parallel trend in memory B cells. A transient increase in regulatory T cells was observed at Week 1 ( p < 0.05). Similar immune changes were observed in sensitivity analysis without corticosteroid use. Conclusion: This study provides the first longitudinal evidence of dynamic changes in innate and adaptive immune compartments during efgartigimod therapy in naive gMG patients. Beyond IgG clearance, efgartigimod might exert targeted immunoregulatory effects on neutrophils and lymphocyte subsets. These findings offer new insights into the broader immunological impact of FcRn‐targeted therapy in gMG and underscore the need for further mechanistic and functional studies.
- 13 October 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (10) , e70627
Open AccessDynamic Changes in Peripheral Immune Cells During Efgartigimod Treatment in Naive Generalized Myasthenia Gravis
Background: Efgartigimod is a neonatal Fc receptor (FcRn) antagonist that reduces pathogenic IgG and improves clinical symptoms in generalized myasthenia gravis (gMG). However, its immunomodulatory effects on innate and adaptive immune cells beyond IgG depletion are rarely reported. Objective: This study aimed to investigate clinical and immunological responses during the initial treatment cycle of efgartigimod in naive acetylcholine receptor antibody‐positive (AChR‐Ab+) gMG patients, with a focus on peripheral immune cell dynamics. Methods: We conducted a longitudinal study between October 23, 2023, and December 10, 2024, based on the database of the Clinical Cohort Study of Myasthenia Gravis at Xuanwu Hospital, Capital Medical University. Seventeen naive AChR‐Ab+ gMG patients were enrolled after applying strict inclusion and exclusion criteria and received a four‐dose regimen of efgartigimod. Clinical efficacy was evaluated using Myasthenia Gravis Activities of Daily Living (MG‐ADL) and Quantitative Myasthenia Gravis (QMG) scores. Serum total IgG and AChR antibody levels were measured. Peripheral immune cell profiling included leukocytes, neutrophils, monocytes, platelets, and natural killer (NK) cells, as well as T and B cell subsets analyzed by flow cytometry. Longitudinal changes were assessed using linear mixed‐effects models. Results: All patients achieved clinical improvement, accompanied by significant reductions in serum total IgG and AChR antibody levels. Neutrophil and leukocyte counts progressively increased and peaked at Week 3 ( p < 0.05), whereas monocyte and platelet counts remained relatively stable throughout all visits. CD4+ and CD8+ T cells decreased transiently at Week 2 and partially recovered by Week 3 ( p = 0.091 and p = 0.005). The CD4/CD8 ratio remained stable. NK cells showed a temporary decrease at Week 2 with a borderline significant time effect ( p = 0.050), followed by partial recovery. Plasmablast proportions significantly increased at Week 2 ( p < 0.05), with a parallel trend in memory B cells. A transient increase in regulatory T cells was observed at Week 1 ( p < 0.05). Similar immune changes were observed in sensitivity analysis without corticosteroid use. Conclusion: This study provides the first longitudinal evidence of dynamic changes in innate and adaptive immune compartments during efgartigimod therapy in naive gMG patients. Beyond IgG clearance, efgartigimod might exert targeted immunoregulatory effects on neutrophils and lymphocyte subsets. These findings offer new insights into the broader immunological impact of FcRn‐targeted therapy in gMG and underscore the need for further mechanistic and functional studies.
- Open Access
- 8 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
Background: Very-late-onset myasthenia gravis (VLOMG) refers to myasthenia gravis (MG) with onset at age 65 or older. Current research on VLOMG prognosis remains limited, especially regarding factors influencing outcomes. Objectives: To identify the clinical factors that affect the short- and long-term prognosis of MG patients with an onset age ⩾65 years. Design: This was a single-center, retrospective cohort study of AChR-ab positive VLOMG patients, classified into two subgroups based on age of onset: sub-very-late-onset MG (S-VLOMG, onset age ⩾65 and <75 years), and super-late-onset MG (SLOMG, onset age ⩾75 years). Methods: A total of 93 patients were included, including 75 in the S-VLOMG group and 18 in the SLOMG group. Clinical, therapeutic, and prognosis data were reviewed, and the Cox regression model was used to identify factors influencing short- and long-term prognosis. Results: Patient characteristics were well balanced between the groups. Overall, 49.5% of patients achieved minimal symptom expression (MSE) within 6 months and 86% within 24 months. There was no significant difference between the groups in the proportion achieving MSE at 6 months ( p = 0.635) or 24 months ( p = 0.714). The median time to achieve MSE was also comparable between the S-VLOMG and SLOMG groups (199.0 days vs 280.5 days, p = 0.463). Low baseline MG-ADL score and steroid therapy were associated with better short-term prognosis ( p = 0.007 and p = 0.002, respectively). For long-term prognosis, baseline bulbar and limb involvement, time to treatment initiation, and use of immunosuppressants were significant factors ( p = 0.025, p = 0.004, p = 0.025, and p < 0.0001, respectively). There were no significant differences in side effects or drug withdrawal rates between two groups. Conclusion: This study demonstrated that AChR-ab positive VLOMG patients have a favorable prognosis and responded well to medication, with age and comorbidities showing no significant impact.
- 8 January 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Open AccessShort-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
Background: Very-late-onset myasthenia gravis (VLOMG) refers to myasthenia gravis (MG) with onset at age 65 or older. Current research on VLOMG prognosis remains limited, especially regarding factors influencing outcomes. Objectives: To identify the clinical factors that affect the short- and long-term prognosis of MG patients with an onset age ⩾65 years. Design: This was a single-center, retrospective cohort study of AChR-ab positive VLOMG patients, classified into two subgroups based on age of onset: sub-very-late-onset MG (S-VLOMG, onset age ⩾65 and <75 years), and super-late-onset MG (SLOMG, onset age ⩾75 years). Methods: A total of 93 patients were included, including 75 in the S-VLOMG group and 18 in the SLOMG group. Clinical, therapeutic, and prognosis data were reviewed, and the Cox regression model was used to identify factors influencing short- and long-term prognosis. Results: Patient characteristics were well balanced between the groups. Overall, 49.5% of patients achieved minimal symptom expression (MSE) within 6 months and 86% within 24 months. There was no significant difference between the groups in the proportion achieving MSE at 6 months ( p = 0.635) or 24 months ( p = 0.714). The median time to achieve MSE was also comparable between the S-VLOMG and SLOMG groups (199.0 days vs 280.5 days, p = 0.463). Low baseline MG-ADL score and steroid therapy were associated with better short-term prognosis ( p = 0.007 and p = 0.002, respectively). For long-term prognosis, baseline bulbar and limb involvement, time to treatment initiation, and use of immunosuppressants were significant factors ( p = 0.025, p = 0.004, p = 0.025, and p < 0.0001, respectively). There were no significant differences in side effects or drug withdrawal rates between two groups. Conclusion: This study demonstrated that AChR-ab positive VLOMG patients have a favorable prognosis and responded well to medication, with age and comorbidities showing no significant impact.